Skip to content
Translational Neuropharmacology Lab (Zanos Lab)

Translational Neuropharmacology Lab (Zanos Lab)

Our laboratory, based in Cyprus, employs molecular and systems neuroscience, behavioral pharmacology, as well as advanced computational methods to unravel the mysteries of brain diseases and identify targets for the development of novel and effective pharmacotherapies.

Menu
  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Welcome to the Zanos Lab – Neuroscience and Pharmacology Research in Cyprus

The Zanos lab (Translational Neuropharmacology Lab) has been established mid-2022 at the University of Cyprus.

We are a dynamic interdisciplinary research team based in the city of Nicosia, Cyprus. Our diverse team brings together a wide range of expertise, including specialists in Drug Repurposing, Molecular and Behavioral Pharmacology, Drug Discovery, Neuroscience, Clinical Psychology, Medicinal Chemistry, and Systems Bioinformatics. Our lab has four main research units:

  • Translational Neuropharmacology
  • Clinical Neuropsychopharmacology
  • Systems Bioinformatics
  • Genetic Epidemiology

Embracing innovation, we integrate experimental techniques, including in vitro, ex vivo, and in vivo rodent models, along with bioinformatics methodologies and genetic epidemiology, to unravel the complexities of different brain diseases, and other comorbid conditions. Our neuroscience and pharmacology research in Cyprus specifically focuses on neurodegenerative and neurodevelopmental diseases, as well as neuropsychiatric disorders.

Notably, we have also made significant strides in clinical research, becoming the first lab in Cyprus to conduct a drug-interventional clinical trial, repurposing the anesthetic drug ketamine for treating opioid use disorders (EudraCT: 2022-001997-70). Building on this success, we are currently leading two additional pioneering clinical trials. The first investigates the associations between emotion regulation ability, stress-induced neural activity changes, and susceptibility to relapse in smokers attempting to quit (NCT06470321). This trial incorporates cortical electroencephalography (EEG) to assess neural activity and stress responses during a 24-hour nicotine abstinence period, followed by a computerized smoking cessation intervention and six months of abstinence monitoring. The second trial, a case-control study, explores the genetic and molecular bases of nicotine addiction to identify potential therapeutic targets (NCT06471387). This study leverages drug repurposing through Mendelian Randomization, a smoking cessation intervention, and the analysis of methylation status in participants undergoing nicotine abstinence. These innovative trials underscore our commitment to translating research into actionable clinical solutions. These innovative trials highlight our leadership in the neuroscience field in Cyprus, translating cutting-edge science into actionable clinical solutions.

In our quest for a healthier future, we go beyond traditional approaches. Our mission extends to exploring the potential of drug repurposing, leveraging the vast knowledge within our team to identify novel solutions for complex conditions. By combining our strengths in diverse fields, we aim to drive innovation and advance our understanding of these intricate disorders.

Our lab is open to new collaborations and welcomes the opportunity to work together with like-minded researchers and organizations. If you share an interest in our lab’s work and envision potential for collaboration, we’d be thrilled to explore new avenues for research and innovation, including the promising realm of drug repurposing. Together, let’s pave the way for transformative discoveries and contribute to the evolving landscape of neuropharmacology research.

 

 

Diversity Statement: The Zanos Lab is committed to fostering a diverse and inclusive environment, recognizing that diversity is essential in scientific research. Embracing multiple perspectives, opinions, and life experiences enables us to be better scientists and achieve superior scientific outcomes. We stand against all forms of racism, inequality, prejudice, and bias. Aligned with the University of Cyprus’ policy, our primary focus is to foster mentees’ growth as scientists in an environment that embraces our common humanity.

 

 

 

University of Cyprus,

Department of  Psychology,

1 Panepistimiou Avenue,

Aglantzia, Nicosia,

2109, Cyprus

 

 

  Connect with us

 

 

Recent Posts

  • Zanos Lab research on biomarkers of nicotine addiction relapse presented at the Hellenic Psychological Society conference May 19, 2025
  • Zanos Lab research decodes molecular pathways in Opioid Use Disorder and Depression at Hellenic Psychological Society conference May 9, 2025
  • Our postdoctoral fellow, Dr. Andria Michael, presents at YUFE4Postdocs workshop in University of Antwerp April 28, 2025
  • Zanos Lab postdoctoral researcher Dr. Polymnia Louka contributes expert article on depression and bone health April 15, 2025
  • Zanos Lab Awarded $100,000 IDSA Foundation Grant for Alzheimer’s Research April 11, 2025

Navigation

  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Translational Neuropharmacology Lab (Zanos Lab) 2025 . Powered by WordPress